LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material Ethacrynic Acid Tablets, USP

25 mg

Manufacturer Lupin Limited

Nagpur 441 108

INDIA

Distributor Lupin Pharmaceuticals, Inc.

111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202

United States

Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion Expected to be non-combustible.

Health All diuretics, including ethacrynic acid, are contraindicated in anuria.

If increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be

discontinued.

In a few patients this diuretic has produced severe, watery diarrhea. If this

occurs, it should be discontinued and not used again.

Until further experience in infants is accumulated, therapy with oral and

parenteral ethacrynic acid is contraindicated.

Hypersensitivity to any component of this product.

EnvironmentNo information is available about the potential of this product to produce

adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

IngredientsCASEthacrynic Acid USP58-54-8

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion Never give anything by mouth to an unconscious person. Wash out

mouth with water. Do not induce vomiting unless directed by medical

personnel. Seek medical attention immediately.

SDS : 209/00 Page 1 of 4

Inhalation Remove to fresh air and keep patient at rest. Seek medical attention

immediately.

Skin ContactWash exposed area with soap and water, remove contaminated clothing

and obtain medical assistance if irritation occurs. This material may not be completely removed by conventional laundering. Consult professional

laundry service. Do not home launder.

Eye Contact Flush eye(s) immediately with plenty of water. If irritation occurs or

persists, get medical attention.

NOTES TO HEALTH PROFESSIONALS

refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGE Overdosage may lead to excessive diuresis with electrolyte depletion

and dehydration.

In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced, or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma, and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment.

In the mouse, the oral LD_{50} of ethacrynic acid is 627 mg/kg and the intravenous LD_{50} of ethacrynate sodium is 175 mg/kg.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards Not applicable

Extinguishing MediaUse carbon dioxide, dry chemical, or water spray.

Special Firefighting Procedures During all fire-fighting activities, wear appropriate protective equipment,

including self-contained breathing apparatus.

Hazardous Combustion Products May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen

oxides, hydrogen chloride, and other chlorine-containing compounds.

Section 6: Accidental Release Measures

Section 6, Accidental release measures

Personal Precautions Personnel involved in clean-up should wear appropriate personal

protective equipment. Minimize exposure.

Environmental Precautions Place waste in an appropriately labeled, sealed container for disposal.

Care should be taken to avoid environmental release.

Clean-up Methods Contain the source of spill if it is safe to do so. Collect spilled material by a

method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

SDS : 209/00 Page 2 of 4

Section 7: Handling and Storage

Section 7, Handling and storage

Handling Avoid generating airborne dust. If tablets or capsules are crushed and/or

broken, avoid breathing dust and avoid contact with eyes.

Storage Store in a tightly closed container at 20°C to 25°C (68° to 77°F); excursions

permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room

Temperature].

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form Ethacrynic acid tablets USP, 25 mg, are white capsule shaped, scored

tablets, and debossed 'L' & 'U' separated with scoreline on one side and

'E67' on the other side. They are supplied as follows:

NDC 68180-159-01 in bottles of 100 Tablets.

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of a tumorigenic effect in a 79-week oral chronic toxicity study in rats at doses up to 45 times the human dose.

Ethacrynic acid had no effect on fertility in a two-litter study in rats or a twogeneration study in mice at 10 times the human dose.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

SDS : 209/00 Page 3 of 4

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

DOT - Not Regulated

DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

SDS : 209/00 Page 4 of 4